Associated Banc Corp Sells 8,204 Shares of Abbott Laboratories $ABT

Associated Banc Corp trimmed its position in Abbott Laboratories (NYSE:ABT) by 6.4% in the 4th quarter, Holdings Channel reports. The firm owned 120,607 shares of the healthcare product maker’s stock after selling 8,204 shares during the quarter. Associated Banc Corp’s holdings in Abbott Laboratories were worth $15,111,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at about $27,000. Cloud Capital Management LLC purchased a new position in Abbott Laboratories in the third quarter worth about $29,000. Guerra Advisors Inc purchased a new position in shares of Abbott Laboratories during the third quarter valued at approximately $31,000. Bridge Generations Wealth Management LLC purchased a new position in shares of Abbott Laboratories during the third quarter valued at approximately $33,000. Finally, Leonteq Securities AG purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $35,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $87.42 on Friday. The firm has a 50-day moving average price of $96.74 and a 200-day moving average price of $112.05. The firm has a market capitalization of $152.27 billion, a PE ratio of 24.49, a price-to-earnings-growth ratio of 1.46 and a beta of 0.65. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the business earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Insider Transactions at Abbott Laboratories

In related news, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the transaction, the vice president owned 24,628 shares of the company’s stock, valued at $2,846,504.24. This trade represents a 2.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by insiders.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: A TipRanks roundup highlighted Abbott as one of three “Strong Buy” dividend aristocrat stocks with more than 15% upside potential, which may support investor confidence in the name. 3 ‘Strong Buy’ Dividend Aristocrat Stocks with 15%+ Upside, 5/22/26
• Positive Sentiment: Another piece argued that Abbott’s Lingo wearable and increased cardiovascular R&D could strengthen its long-term growth outlook by expanding its health-tech and diagnostics footprint. Abbott’s Lingo Wearable And Cardio R&D Reframe Long Term Growth Story
• Neutral Sentiment: One market note said traders are waiting for more clarity on integration results, suggesting investors are in a “show-me” phase rather than fully repricing the stock higher. Waiting on Integration Result, Market Stays Moderated on Abbott Laboratories (ABT)
• Negative Sentiment: Another article said Abbott has been “slid” in part because its nutrition segment is sensitive to consumer spending trends, highlighting macro pressure on a key business line. Abbott Laboratories (ABT) Slid Due To Its Nutrition Segment’s Sensitivity to Consumer Spending Momentum
• Negative Sentiment: Goldman Sachs reportedly removed Abbott from its U.S. Conviction List, which may weigh on sentiment even though it does not change the company’s fundamentals. Why UnitedHealth (UNH) Remains a Turnaround Bet Despite Policy and Cost Pressure

Analyst Ratings Changes

A number of analysts have commented on the stock. Sanford C. Bernstein reduced their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Argus dropped their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. Stifel Nicolaus dropped their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Piper Sandler lowered their price objective on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Finally, Bank of America lowered their price objective on shares of Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $119.43.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.